Table 2.
Clinical trials of frovatriptan for acute treatment of menstrual migraine: post hoc analyses of three placebo-controlled RCTs
| Study | Intervention | Results of primary end points |
|---|---|---|
| Allais et al (2011)65 | Frovatriptan 2.5 mg (73 attacks); zolmitriptan 2.5 mg (65 attacks) | Pain relief at 2 hours: 52% frovatriptan; 53% zolmitriptan (NS) |
| Pain-free at 2 hours: 22% frovatriptan; 26% zolmitriptan (NS) | ||
| Pain relief at 24 hours: 83% frovatriptan; 82% zolmitriptan (NS) | ||
| Pain-free at 24 hours: 74% frovatriptan; 69% zolmitriptan (NS) | ||
| Relapse within 24 hours: 15% frovatriptan; 22% zolmitriptan (P<0.05) | ||
| Bartolini et al (2012)66 | Frovatriptan 2.5 mg (77 attacks); almotriptan 12.5 mg (78 attacks) | Pain relief at 2 hours: 36% frovatriptan; 41% almotriptan (NS) |
| Pain-free at 2 hours: 19% frovatriptan; 29% almotriptan (NS) | ||
| Pain relief at 24 hours: 62% frovatriptan; 67% almotriptan (NS) | ||
| Pain-free at 24 hours: 60% frovatriptan; 67% almotriptan (NS) | ||
| Relapse within 24 hours: 8% frovatriptan; 21% almotriptan (P<0.05) | ||
| Savi et al (2011)67 | Frovatriptan 2.5 mg (49 attacks); rizatriptan 5 mg (59 attacks) | Pain relief at 2 hours: 58% frovatriptan; 64% rizatriptan (NS) |
| Pain-free at 2 hours: 31% frovatriptan; 34% rizatriptan (NS) | ||
| Pain relief at 24 hours: 81% frovatriptan; 74% rizatriptan (NS) | ||
| Pain-free at 24 hours: 67% frovatriptan; 61% rizatriptan (NS) | ||
| Relapse within 24 hours: 10% frovatriptan; 32% rizatriptan (P<0.01) | ||
| Allais et al (2012)68 | Pooled data from Frovatriptan 2.5 mg (199 attacks); almotriptan 12.5 mg/rizatriptan 5 mg/zolmitriptan 2.5 mg (202 attacks)63–65 | Pain relief at 2 hours: 37% frovatriptan; 43% other triptans (NS) |
| Pain-free at 2 hours: 23% frovatriptan; 30% other triptans (NS) | ||
| Pain relief at 24 hours: 37% frovatriptan; 43% other triptans (NS) | ||
| Pain-free at 24 hours: 23% frovatriptan; 30% other triptans (NS) | ||
| Relapse within 24 hours: 11% frovatriptan; 24% other triptans (P<0.05) | ||
| Allais et al (2013)69 | Oral contraceptive-induced migraine in pooled data from frovatriptan 2.5 mg (73 attacks); almotriptan 12.5 mg/rizatriptan 5 mg/zolmitriptan 2.5 mg (71 attacks)63–65 | Pain relief at 2 hours: 51% frovatriptan; 48% other triptans (NS) |
| Pain-free at 2 hours: 25% frovatriptan; 28% other triptans (NS) | ||
| Pain relief at 24 hours: 83% frovatriptan; 76% other triptans (NS) | ||
| Pain-free at 24 hours: 71% frovatriptan; 60% other triptans (P<0.05) | ||
| Relapse within 24 hours: 17% frovatriptan; 27% other triptans (P<0.05) |
Notes: Pain relief: decrease in migraine from severe or moderate to mild or no headache. Pain-free: absence of migraine 2 hours after intake of one dose of study drug ± rescue medication. Relapse: migraine occurring 24 hours after the previous episode, with a migraine-free period between the two attacks.
Abbreviations: NS, nonsignificant; RCT, randomized controlled trial.